Liao Yang, Liu Fei, Zhang Xiaozhou, Yang Nan
Department of Hepatobiliary Surgery, Zigong First People's Hospital, # 42, Shangyihao 1St Branch Road, Ziliujing District, Zigong, 643000, Sichuan, China.
Department of Gastroenterology, Zigong First People's Hospital, Zigong, Sichuan, China.
Updates Surg. 2024 Dec;76(8):2767-2775. doi: 10.1007/s13304-024-02034-8. Epub 2024 Nov 25.
While laparoscopic common bile duct exploration with primary duct closure (LCBDE + PDC) has been considered a feasible and safe treatment for cholecystocholedocholithiasis, uncertainties remain regarding its effectiveness and safety in patients with mild-to-moderate calculus-associated acute cholangitis. Therefore, this study aims to investigate the safety and efficacy of LCBDE + PDC specifically in patients with mild-to-moderate acute cholangitis (AC). Patients with cholecystocholedocholithiasis who underwent LCBDE + PDC treatment at our hospital between July 2020 and September 2022 were included. The patients were divided into two groups based on the presence of cholangitis: acute cholangitis (AC group) and non-acute cholangitis (non-AC group). A total of 136 patients underwent LCBDE + PDC treatment, with 65 in the AC group and 71 in the non-AC group. No deaths occurred after surgery in either group. The AC group had longer drainage tube retention time (5 (4-7) days vs. 4 (3-5) days, P < 0.001), postoperative hospital stay (8 (6-9) days vs. 6 (5-7) days, P < 0.001), and total hospital stay (12 (9.5-15) days vs. 10 (8-13) days, P < 0.001) compared to the non-AC group. However, there were no significant differences between the two groups in terms of operation time, estimated blood loss, and the rate of using holmium laser lithotripsy. The incidence of postoperative complications was similar between the two groups. Our study demonstrates that LCBDE + PDC is a safe and feasible treatment for patients with mild-to-moderate calculus-associated acute cholangitis who meet the criteria for primary duct closure.
虽然腹腔镜胆总管探查并一期缝合(LCBDE+PDC)已被认为是治疗胆囊胆总管结石的一种可行且安全的方法,但对于轻至中度结石相关性急性胆管炎患者,其有效性和安全性仍存在不确定性。因此,本研究旨在探讨LCBDE+PDC在轻至中度急性胆管炎(AC)患者中的安全性和有效性。纳入2020年7月至2022年9月在我院接受LCBDE+PDC治疗的胆囊胆总管结石患者。根据是否存在胆管炎将患者分为两组:急性胆管炎组(AC组)和非急性胆管炎组(非AC组)。共有136例患者接受了LCBDE+PDC治疗,其中AC组65例,非AC组71例。两组术后均无死亡病例。与非AC组相比,AC组的引流管留置时间更长(5(4 - 7)天 vs. 4(3 - 5)天,P < 0.001)、术后住院时间更长(8(6 - 9)天 vs. 6(5 - 7)天,P < 0.001)以及总住院时间更长(12(9.5 - 15)天 vs. 10(8 - 13)天,P < 0.001)。然而,两组在手术时间、估计失血量和使用钬激光碎石术的比例方面无显著差异。两组术后并发症的发生率相似。我们的研究表明,LCBDE+PDC对于符合一期缝合标准的轻至中度结石相关性急性胆管炎患者是一种安全可行的治疗方法。